Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories
-
uniQure to Participate in Multiple Upcoming Industry Conferences in October
-
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
-
uniQure to Participate in Multiple Upcoming Industry Conferences in April
-
uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
-
uniQure to Participate in Multiple Upcoming Industry Conferences in October
-
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
-
uniQure BV (QURE) PT Lowered to $105 at Chardan Capital Markets
-
uniQure to Participate in Multiple Upcoming Industry Conferences in March
-
uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
-
uniQure to Participate in Multiple Upcoming Industry Conferences in October
-
uniQure BV (QURE) PT Raised to $175 at Chardan Capital Markets
-
uniQure BV (QURE) PT Raised to $100 at Chardan Capital Markets
-
Pre-Open Stock Movers 02/25: (ONCE) (CMTA) (QURE) Higher; (MDR) (CRON) (NBR) Lower (more...)
-
uniQure BV (QURE) Named Top 2019 Pick at Chardan
-
uniQure BV (QURE) PT Raised to $70 at Chardan Capital Markets
-
uniQure to Participate in Multiple Upcoming Industry Conferences
-
Chardan Capital Markets Reiterates Buy on uniQure (QURE) Following New FDA Guidelines on Gene Therapy
-
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
-
uniQure (QURE) Prices 4.5M Share Offering at $28.50/Sh
-
uniQure Announces Pricing of its Public Offering
-
uniQure Announces Closing of its Public Offering
-
uniQure (QURE) Prices 5M Share Common Offering at $18.25/Sh
-
uniQure Announces Pricing of its Public Offering
-
uniQure (QURE) to Offer 5M Shares
-
uniQure Announces Proposed Public Offering
-
Pre-Open Stock Movers 10/20: (SKX) (TEAM) (QURE) Higher; (DRRX) (NCR) (CELG) (GE) Lower (more...)
-
After-Hours Stock Movers 10/19: (SKX) (TEAM) (IMPV) (PYPL) Higher; (NCR) (CELG) (ATHN) Lower (more...)
-
uniQure BV (QURE) PT Raised 180% to $35 at Chardan Capital Markets; Sees Heb B Leadership in GT
-
uniQure (QURE) Breakthrough Therapy Designation an 'Important Positive' - Chardan Capital Markets
-
uniQure (QURE) PT Cut to $12 at Chardan Capital Markets; 'Buy' Maintained on Simplification
-
Green Shoots in uniQure (QURE) POC Data - Chardan Capital Markets
-
Chardan Capital Says uniQure (QURE) on Pullback, Slight Delay to AMT-060 is Immaterial
-
Streetinsider.com's Hot Lunchtime Reads 8/27: (TSLA) (RJET) (QURE) (WSM)
-
Chardan Capital Trims PT on uniQure (QURE) to $35; Notes Uncertainty of Glybera in the U.S.
-
Notable Analyst Rating Changes 4/24: (MAT) (TEL) (CVC) Upgraded; (BBY) (NKE) (GM) Downgraded
-
Chardan Capital Markets Starts uniQure BV (QURE) at Buy; Sees 2015 as 'Breakthrough' Year

